We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 143.00 | 151.00 | 170.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
27/3/2021 16:09 | Amryt has stated in the March corporate presentation (see website) that "Q1 2021- Oleogel-S10 FDA & EMA filings" so this is not something that should be a surprise. | whatno | |
27/3/2021 15:49 | There has clearly been an overhang. Happy to hold and see out all 2021 | moorsie2 | |
26/3/2021 22:17 | "Has the overhang been cleared? Some decent sized late reported trades.. FDA Application for Filsuvez should be filed early next week.. Hopefully!" >>>>> Posted today by knowledgeable Irish based investor, Bronxville, on the lse AMYT bb. Let's hope he's correct regarding the FDA and Filsuvez. | papillon | |
25/3/2021 23:54 | Regarding Ray Stafford's recent purchase of 300,100 shares @ £2, I wonder why he purchased the shares on the LSE and not Nasdaq? After all when AMYT listed on Nasdaq the Directors said they were in the process of transferring all of their shareholdings from the LSE to Nasdaq. | papillon | |
25/3/2021 21:39 | Whooooosh, one of my favourite words!! | bazworth | |
25/3/2021 21:00 | The share price is drifting back to the price before we had all the positive rns throughout this month.The company is growing from strength to strength unfortunately the share price doesnt seem to reflect the progress :-(One day, one day when we least expect it we get that well deserved wooooosh | digadee | |
23/3/2021 23:43 | free stock charts from uk.advfn.com free stock charts from uk.advfn.com God only knows where the April dates shown on the advfn charts come from. Lets hope that the bottom of the Ichimoku "cloud" acts as support on both the lse & Nasdaq charts. | papillon | |
23/3/2021 18:14 | Paps - I have a similar story, although I have been in and out a few times since the fastnet days. You are absolutely right that anticipated news rarely moves a share price (much) - I think there has also been a change in sentiment in the US given the dive in Nasdaq listed stocks of late. Amryt is not the most exciting share but at least there don't appear to be any skeletons in the cupboard that are likely to cause a 50% overnight loss (which I have had happened with other biotechs). The news today regarding PL in the US does suggest that they have a high probability of significantly increasing revenues from Metreleptin - albeit from 2023 onwards. I'm not aware of any other drug being developed for this indication that could cause clouds on the horizon. I would hope that FDA acceptance of the Fulsivez NDA (assuming that happens) might at least generate some more enthusiasm from investors.. | whatno | |
23/3/2021 17:22 | Join the club, whatno! I've got this wrong ever since I first bought into FAST around 6 years ago, when it was basically a cash shell, thinking (and hoping) it would return it's cash to shareholders, or line up a juicy acquisition. It did neither: instead a boring and with the benefit of hindsight, a vastly over priced, company RTO'd into FAST and became AMYT! I've hung on ever since, whilst it's great hope AP101 suffered delay, after delay. Initially the RTO placing was at 24p (= 144p), but the share price has failed to perform during the almost 5 years since the RTO. Along the way Amicus's competitor to AP101 (for which Amicus paid Socioderm a lot of money) failed phase 3 and that set AMYT back and led to changes to it's AP101 phase 3 trials. Cathal Friel, who was behind FAST and the AMYT RTO, got fed up and exited AMYT and has done spectacularly well with his next biotech vehicle, ORPH, courtesy of COVID 19. However I'm still clinging on! And will continue to cling on until AP101 (or whatever they call it these days!) gets (or doesn't get) FDA approval and AMYT gets loads of dollars for selling on it's fast track approval. I live in hope! PS There's a fair bit of chart support @ circa £2. Will it hold? We'll have to wait and see. | papillon | |
23/3/2021 15:43 | Paps - I stand corrected :-) | whatno | |
23/3/2021 14:33 | As each day passes here I sounding more and more like Victor Meldrew............. | richpassi | |
23/3/2021 14:02 | Funny old game!! | bazworth | |
23/3/2021 08:49 | Great news... So it falls.. | babbler | |
23/3/2021 08:38 | I imagine this will get US investors interested. Generally, anything with FDA in the press release wakes them up. | whatno | |
23/3/2021 07:41 | That's disappointing to have more good news, not sure if the share price can take too much more of it... | cwa1 | |
23/3/2021 07:08 | They don’t hang around, do they! | bazworth | |
23/3/2021 07:05 | More good news | alphabravo321 | |
22/3/2021 11:17 | I've never understood why Broker's price targets exist at all as they mostly appear nonsensical a best! Would seem a complete waste of time and of the cash paying for their completion!! | bazworth | |
22/3/2021 10:40 | I wouldn't take any notice of broker price targets, Moorsie2, especially not an share price prediction from Davy. I remember once upon a time they predicted £23 for PVR, who are currently under 5p.🤣 I recall someone posting that broker share price forecasts should be halved and then halved again! PS. Davy are currently in very hot water in Ireland for some very dodgy dealing. Definitely a broker to avoid when it comes to price predictions! | papillon | |
22/3/2021 10:28 | I would have thought the FDA submission would wake up US investors. However, You can't ignore the risk-off change in sentiment in the US (Nasdaq) - this has had a marked effect on growth stocks. | whatno |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions